Antimicrobial resistance and treatment of community-acquired pneumonia
1Division of Infectious Diseases, McMaster University, Henderson Site, 711 Concession Street, 40 Wing, 5th floor, Room 503, Hamilton, Ontario L8V 1C3, Canada. lmandell@mcmaster.cs
Clinics in Chest Medicine
|April 2, 2005
Abstract:
This article discusses the problem of antimicrobial resistance and how it affects the management of community-acquired pneumonia (CAP). The discussion is limited to infection with Streptococcus pneumoniae and to the treatment of patients hospitalized in a medical ward or an intensive care unit because of pneumococcal CAP.
Insights
Antimicrobial resistance complicates the treatment of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae. This review focuses on managing hospitalized patients with pneumococcal CAP, considering resistance challenges.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Antimicrobial resistance is a growing global health threat.
- Community-acquired pneumonia (CAP) remains a significant cause of morbidity and mortality.
- Streptococcus pneumoniae is a primary pathogen responsible for CAP.
Purpose of the Study:
- To review the impact of antimicrobial resistance on the management of pneumococcal CAP.
- To discuss treatment strategies for hospitalized patients with CAP due to Streptococcus pneumoniae.
Main Methods:
- Literature review focusing on antimicrobial resistance in Streptococcus pneumoniae.
- Analysis of treatment guidelines and clinical data for CAP management.
- Discussion of therapeutic options for inpatient settings.
Main Results:
- Increasing resistance rates of Streptococcus pneumoniae to common antibiotics pose treatment challenges.
- Empirical antibiotic selection requires careful consideration of local resistance patterns.
- Treatment failure can occur due to antimicrobial resistance.
Conclusions:
- Effective management of pneumococcal CAP necessitates awareness of antimicrobial resistance.
- Optimizing antibiotic therapy is crucial to improve patient outcomes.
- Continued surveillance of resistance is essential for public health.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...